WallStSmart

Brookfield Corp (BN)vsHelius Medical Technologies Inc Class A (HSDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Brookfield Corp generates 824939% more annual revenue ($79.11B vs $9.59M). BN leads profitability with a 1.7% profit margin vs 0.0%. BN earns a higher WallStSmart Score of 63/100 (C+).

BN

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 5.5Value: 4.3Quality: 4.0
Piotroski: 5/9Altman Z: 0.64

HSDT

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 4/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BN4 strengths · Avg: 8.8/10
EPS GrowthGrowth
158.8%10/10

Earnings expanding 158.8% YoY

Market CapQuality
$101.83B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
28.9%8/10

Strong operational efficiency at 28.9%

HSDT2 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
7290.0%10/10

Revenue surging 7290.0% year-over-year

Areas to Watch

BN4 concerns · Avg: 2.5/10
Return on EquityProfitability
2.8%3/10

ROE of 2.8% — below average capital efficiency

Profit MarginProfitability
1.7%3/10

1.7% margin — thin

P/E RatioValuation
89.4x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-5.60B2/10

Negative free cash flow — burning cash

HSDT4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$74.15M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-137.4%2/10

ROE of -137.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BN

The strongest argument for BN centers on EPS Growth, Market Cap, Price/Book. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : HSDT

The strongest argument for HSDT centers on Price/Book, Revenue Growth. Revenue growth of 7290.0% demonstrates continued momentum.

Bear Case : BN

The primary concerns for BN are Return on Equity, Profit Margin, P/E Ratio. A P/E of 89.4x leaves little room for execution misses. Debt-to-equity of 5.72 is elevated, increasing financial risk.

Bear Case : HSDT

The primary concerns for HSDT are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

BN profiles as a value stock while HSDT is a hypergrowth play — different risk/reward profiles.

BN carries more volatility with a beta of 1.85 — expect wider price swings.

HSDT is growing revenue faster at 7290.0% — sustainability is the question.

HSDT generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

BN scores higher overall (63/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brookfield Corp

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Brookfield Corporation is an alternative asset manager and REIT/Real Estate Investment Manager firm focuses on real estate, renewable power, infrastructure and venture capital and private equity assets. The company is headquartered in Toronto, Canada with additional offices across Northern America; South America; Europe; Middle East and Asia.

Helius Medical Technologies Inc Class A

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing and acquiring non-invasive technologies for the treatment of symptoms caused by neurological diseases or trauma. The company is headquartered in Newtown, Pennsylvania.

Want to dig deeper into these stocks?